Claims for Patent: 9,365,500

Summary for Patent: 9,365,500

Title:	9-aminomethyl substituted minocycline compounds
Abstract:	The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
Inventor(s):	Nelson; Mark L. (Norfolk, MA), Frechette; Roger (Reading, MA), Ismail; Mohamed Y. (Bedford, MA), Honeyman; Laura (Etobicoke, CA), Bowser; Todd (Charlton, MA), Bhatia; Beena (Mansfield, MA)
Assignee:	PARATEK PHARMACEUTICALS, INC. (Boston, MA)
Application Number:	14/318,031
Patent Claims:	1. A method for treating a bacterial infection in a subject, comprising administering to said subject a compound having the following structure: ##STR00044## or a pharmaceutically acceptable salt or ester thereof. 2. The method of claim 1, wherein said bacterial infection is associated with gram positive bacteria. 3. The method of claim 1, wherein said bacterial infection is associated with gram negative bacteria. 4. The method of claim 1, wherein said bacterial infection is associated with E. coli. 5. The method of claim 1, wherein said bacterial infection is associated with S. aureus. 6. The method of claim 1, wherein said bacterial infection is associated with E. faecalis. 7. The method of claim 1, wherein said bacterial infection is resistant to other tetracycline antibiotics. 8. The method of claim 1, wherein said compound is administered with a pharmaceutically acceptable carrier. 9. The method of claim 1, wherein said subject is a mammal. 10. The method of claim 1, wherein said subject is a human. 11. A method for treating a bacterial infection in a subject, comprising administering to said subject a compound having the following structure: ##STR00045## or a pharmaceutically acceptable salt thereof. 12. The method of claim 11, wherein said bacterial infection is associated with gram positive bacteria. 13. The method of claim 11, wherein said bacterial infection is associated with gram negative bacteria. 14. The method of claim 11, wherein said bacterial infection is associated with E. coli. 15. The method of claim 11, wherein said bacterial infection is associated with S. aureus. 16. The method of claim 11, wherein said bacterial infection is associated with E. faecalis. 17. The method of claim 11, wherein said bacterial infection is resistant to other tetracycline antibiotics. 18. The method of claim 11, wherein said compound is administered with a pharmaceutically acceptable carrier. 19. The method of claim 11, wherein said subject is a mammal. 20. The method of claim 11, wherein said subject is a human. 21. A method for treating a bacterial infection in a subject, comprising administering to said subject a pharmaceutically acceptable salt of the compound having the following structure: ##STR00046## 22. The method of claim 21, wherein said bacterial infection is associated with gram positive bacteria. 23. The method of claim 21, wherein said bacterial infection is associated with gram negative bacteria. 24. The method of claim 21, wherein said bacterial infection is associated with E. coli. 25. The method of claim 21, wherein said bacterial infection is associated with S. aureus. 26. The method of claim 21, wherein said bacterial infection is associated with E. faecalis. 27. The method of claim 21, wherein said bacterial infection is resistant to other tetracycline antibiotics. 28. The method of claim 21, wherein said compound is administered with a pharmaceutically acceptable carrier. 29. The method of claim 21, wherein said subject is a mammal. 30. The method of claim 21, wherein said subject is a human. 31. The method of claim 1, wherein said bacterial infection is associated with K. pneumoniae. 32. The method of claim 1, wherein said bacterial infection is associated with Salmonella. 33. The method of claim 1, wherein said bacterial infection is associated with E. hirae. 34. The method of claim 1, wherein said bacterial infection is associated with A. baumanii. 35. The method of claim 1, wherein said bacterial infection is associated with B. catarrhalis. 36. The method of claim 1, wherein said bacterial infection is associated with H. influenzae. 37. The method of claim 1, wherein said bacterial infection is associated with P. aeruginosa. 38. The method of claim 1, wherein said bacterial infection is associated with E. faecium. 39. The method of claim 11, wherein said bacterial infection is associated with K. pneumoniae. 40. The method of claim 11, wherein said bacterial infection is associated with Salmonella. 41. The method of claim 11, wherein said bacterial infection is associated with E. hirae. 42. The method of claim 11, wherein said bacterial infection is associated with A. baumanii. 43. The method of claim 11, wherein said bacterial infection is associated with B. catarrhalis. 44. The method of claim 11, wherein said bacterial infection is associated with H. influenzae. 45. The method of claim 11, wherein said bacterial infection is associated with P. aeruginosa. 46. The method of claim 21, wherein said bacterial infection is associated with E. faecium. 47. The method of claim 21, wherein said bacterial infection is associated with K. pneumoniae. 48. The method of claim 21, wherein said bacterial infection is associated with Salmonella. 49. The method of claim 21, wherein said bacterial infection is associated with E. hirae. 50. The method of claim 21, wherein said bacterial infection is associated with A. baumanii. 51. The method of claim 21, wherein said bacterial infection is associated with B. catarrhalis. 52. The method of claim 21, wherein said bacterial infection is associated with H. influenzae. 53. The method of claim 21, wherein said bacterial infection is associated with P. aeruginosa. 54. The method of claim 21, wherein said bacterial infection is associated with E. faecium.